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ABSTRACT
The role of IL-2 in HSC maintenance is unknown. Here we show that Il2-/- mice 
develop severe anomalies in HSC maintenance leading to defective hematopoiesis. 
Whereas, lack of IL-2 signaling was detrimental for lympho- and erythropoiesis, 
myelopoiesis was enhanced in Il2-/- mice. Investigation of the underlying mechanisms 
of dysregulated hematopoiesis in Il2-/- mice shows that the IL-2-Treg cell axis is 
indispensable for HSC maintenance and normal hematopoiesis. Lack of Treg activity 
resulted in increased IFN-γ production by activated T cells and an expansion of the 
HSCs in the bone marrow (BM). Though, restoring Treg population successfully rescued 
HSC maintenance in Il2-/- mice, preventing IFN-γ activity could do the same even in 
the absence of Treg cells. Our study suggests that equilibrium in IL-2 and IFN-γ activity 
is critical for steady state hematopoiesis, and in clinical conditions of BM failure, IL-2 
or anti-IFN-γ treatment might help to restore hematopoiesis.
INTRODUCTION
In vertebrates, postnatal hematopoiesis mainly 
occurs in the bone marrow (BM). Through a complex 
but precisely regulated differentiation process the 
hematopoietic stem cells (HSC) give rise to mature 
blood cells of all lineages. HSC niche-derived signals, 
originating from cells as diverse as the osteoblasts, 
endothelial cells, Cxcl12-abundant reticular (CAR) cells, 
Nestin+ mesenchymal stem cells etc., and a host of cell-
intrinsic factors, such as Notch1, Runx1, GATA2, and SCL 
etc. play a key role in the maintenance of HSCs in the BM 
[1-10]. HSCs possess the unique traits of quiescence, and 
the ability to self-renew, which are absolutely critical for 
the general well-being and longevity of any organism as 
HSCs are the sole source for replenishment of all types 
of blood cells in case of demands that arise under various 
physiological and pathological conditions [11, 12].
Phenotypically HSCs are characterized as the 
lineage marker-negative (Lin-), stem cell antigen-1 (Sca1) 
and the stem cell factor receptor (SCFR or c-Kit) positive 
(Lin-Sca1+c-Kit+: LSK) cells in the BM. Various in vivo 
and in vitro analyses of LSK cells identified two distinct 
populations, the long- and the short-term repopulating 
stem cells (LT-HSC and ST-HSC). The LT-HSCs, which 
do not express the fetal liver kinase-2 (Flk2) on their 
surface, retain the ability for life-long self-renew and at 
the same time give rise to the ST-HSCs, whereas the Flk2 
expressing ST-HSCs are capable of limited self-renewal 
and give rise to the multipotent progenitor cells for all 
blood lineages [13]. Maintenance of HSC quiescence is 
vital to prevent exhaustion and thereby for the integrity of 
the hematopoietic system [14, 15]. Cytokines and growth 
factors form an important class of regulatory molecules, 
which are indispensable for the maintenance of HSC 
quiescence [16-21]. Though, recent studies have identified 
many such cytokines, chemokines and other hematopoietic 
growth factors, a role for the primarily lymphocyte-
specific growth factor interleukin-2 (IL-2) has not been 
identified.
In T cells, IL-2 binds to a heterotrimeric receptor 
consisting of the IL-2 receptor α (IL-2Rα, CD25), IL-
2Rβ (CD122) and the common γ (CD132, γc) chain 
[22, 23]. Upon ligation, IL-2 activates the receptor 
bound tyrosine kinases Jak1 and Jak3, which in turn 
phosphorylate the signal transducer and activator of 
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transcription 5 (STAT5) transcription factors (TF) [24-26]. 
Activated STAT5 subsequently regulate the expression 
of various target genes that executes IL-2 signals [27-
29]. IL-2 is mainly produced by activated CD4+ and 
CD8+ T cells, and plays a critical role in the survival 
and proliferation of lymphocytes [22, 23, 30-33]. Recent 
studies have established the indispensable role of IL-2 in 
the maintenance of the CD4+CD25+Foxp3+ regulatory T 
(Treg) cells, which are vital to keep immune homeostasis 
in place [23, 34, 35]. Lack of IL-2 signaling results in the 
death of Treg cells leading to rapid development of various 
autoimmune disorders, such as lymphoproliferation, 
colitis etc., [36-39]. A similar phenotype has also been 
reported for mice deficient in Foxp3 or any component 
of IL-2 signaling pathway [30, 40]. In addition, humans 
having an inactivating mutation in the Foxp3 gene 
suffer from a severe autoimmune pathology called IPEX 
(Immunodysregulation Polyendocrinopathy Enteropathy 
X-linked) syndrome [41]. Thus, the role of IL-2 in T cell 
function and in maintaining immune homeostasis is well 
established. 
We have recently reported that IL-2 plays a critical 
role in maintaining erythropoiesis by modulating Treg 
cell activity in the BM [42]. However, the influence of 
IL-2 on HSC generation or maintenance in the BM has 
not yet been investigated. In this study we have analysed 
whether lack of IL-2 signaling has any influence on 
hematopoiesis and report that the IL-2-Treg-Teff cell axis 
plays an indispensable role in maintaining steady state 
HSC population in the BM. Deficiency in IL-2 signaling 
results in an IFN-γ-mediated disruption of equilibrium in 
HSC physiology leading to impaired hematopoiesis, which 
might be a major contributing factor towards the severe 
phenotype observed in all IL-2 signaling deficient mice, 
and most likely also in humans. 
RESULTS
Impaired HSC maintenance in Il2-/- mice
To investigate whether IL-2 deficiency affects 
hematopoiesis, we first of all analysed the distribution 
of HSCs in Il2-/- mice. Evaluation of BM cells revealed a 
strong increase in LSK population in Il2-/- mice compared 
to WT mice (Figure 1A). The increased LSK population 
in Il2-/- mice was gender-independent and was observed 
both in proportion (Figure 1B) and in absolute numbers 
(Figure 1C). Interestingly, though the Il2-/- LSK cells were 
slightly bigger in size (Figure 1D, 1F), they showed a 
markedly higher granularity compared to WT LSK cells 
(Figure 1E, 1F). We also observed a consistently strong 
increase in Lin-Sca1+c-Kit- (Sca1+) cells in Il2-/- mice, 
whereas the distribution of Lin-Sca1-c-Kit+ (c-Kit+) cells 
was similar compared to WT mice (Figure 1A). However, 
the increase in LSK cells in Il2-/- mice was independent 
of the impairment in Sca1+ population in these mice. 
Compared to LSK cells, Il2-/- Sca1+ and c-Kit+ cells 
showed distinct patterns in their cell size and granularity, 
comparable with that of WT mice (Figure 1G, 1H and 
Supplementary Figure 1A, B). In addition, HSC analysis 
in BM using CD48 and CD150 as markers also showed 
an increase in HSC (Lin-c-Kit+CD48-CD150+) population 
in the Il2-/- mice compared to WT mice (Figure 1I). This 
further ruled out any possible contamination from cells 
expressing Sca1 in the perturbed HSC (LSK) population 
in Il2-/- mice. Similar to BM, impaired HSC distribution 
was also observed in the spleen of Il2-/- mice suggesting 
a systemic defect in HSC maintenance in the absence of 
IL-2 signaling (Supplementary Figure 1C, D).
Analysis of mature hematopoietic cell populations 
in WT and Il2-/- mice revealed a drastically altered 
distribution of lymphoid (CD3+, B220+ and NK1.1+), 
myeloid (CD11b+, CD11c+, Gr1+ and F4/80+) and 
erythroid (Ter119+ and CD41+) lineage cells in Il2-/- mice 
BM (Supplementary Figure 1E). In general, in Il2-/- mice 
myelopoiesis was strongly increased over the impaired 
lympho- and erythropoiesis, indicating a myeloid bias of 
the Il2-/- HSC compared to WT controls (Supplementary 
Figure 1E). This myeloid-biased hematopoiesis was 
supported by an increased expression of myeloid-
specific genes (Cebpa, Csf3r, Csf2ra, Csf1r and Il3ra) 
in the Il2-/- mice (Figure 1J). To dissect this severely 
perturbed hematopoiesis, we next investigated whether 
the distribution of the LT- and the ST-HSCs are altered 
in the context of IL-2 deficiency. Intriguingly, analysis of 
Flk2 expression revealed a significant increase in Flk2- LT-
HSC and a corresponding decrease in the Flk2+ ST-HSC 
in Il2-/- mice compared to that in WT mice (Figure 1K, 
1L). Moreover, the defective hematopoiesis in absence 
of IL-2 signaling was readily evident from the forward 
(FSC) and side scatter (SSC) distribution of the BM cells 
as a clear loss of FSCloSSClo and an increase in FSChiSSChi 
cells was observed in Il2-/- mice compared to the WT 
mice (Figure 1M, 1N). The impairment in Il2-/- HSC was 
further confirmed as we observed a suppressed Flk2 and 
an enhanced Slamf1 (Cd150) expression in the LSK cells 
from Il2-/- mice, which was exactly opposite in the WT 
LSK cells (Figure 1O). Previous studies have implicated 
the criticality of Notch signaling and the Runx TFs in the 
generation and proliferation of HSC [7]. Interestingly, a 
strong increase in Notch (Notch1 and Notch2) and Runx1 
expression was evident in the Il2-/- LSK cells suggesting 
that enhanced Notch-Runx1 activity could be the factor 
promoting dysregulated HSC maintenance in Il2-/- mice 
(Figure 1P). Additionally, in Il2-/- mice the expression 
of Scl, Cxcr4 and cMpl, the key signalling molecules 
regulating HSC maintenance were also altered [9, 10, 
18, 43-46] (Figure 1P). Further, analysis of TFs involved 
in HSC quiescence revealed a dose-dependent increase 
in their expression in Il2-/- HSCs [47-56] compared to 
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WT cells (Figure 1Q). Interestingly, the Il2-/- LSK cells 
expressed higher levels of Bcl2 and Bcl2l1, indicating 
that the dysregulated hematopoiesis in Il2-/- mice was 
not due to the death of HSCs (Figure 1R). Also, in line 
with the increased number of LSK cells, expression of 
the cell cycle inhibitor p27kip1 (Cdkn1b) was strongly 
downregulated and genes regulating HSC expansion were 
enhanced in the Il2-/- mice (Figure 1R).
Next, we investigated whether the HSC defects 
observed in Il2-/- mice are replicated in all mice that lack 
IL-2 signaling. Analysis of Il2ra-/- or Jak3-/- mice showed 
a similar increase in LSK cells, and a loss of FSCloSSClo 
BM cells with corresponding increase in FSChiSSChi 
cells as was observed in Il2-/- mice suggesting a specific 
influence of lack of IL-2 signaling on HSC maintenance 
(Supplementary Figure 1F-K).
IL-2 signaling influences hematopoiesis
To explore if IL-2 signals influence HSC 
maintenance, we adoptively transferred CD45.1+ WT BM 
cells to lethally irradiated CD45.2+ WT or Il2-/- mice and 
analysed donor-derived cells-specific hematopoiesis in the 
recipient mice. Analysis of LSK cells in the BM 5 weeks 
post-transfer revealed an increase in donor-derived LSK 
cells in the Il2-/- recipients compared to the WT recipients 
replicating a phenotype observed in Il2-/- mice (Figure 
2A). This pattern persisted even at 11 weeks after BM 
cell transfer (Figure 2A), suggesting a disturbed HSC 
maintenance in an IL-2-deficient environment. In addition, 
similar to Il2-/- mice, Il2-/- recipients showed increased 
Sca1+ cells in the BM both at 5 and 11 weeks after cell 
transfer (Supplementary Figure 2A). Further, the thymus, 
spleen and BM cellularity in the Il2-/- recipients was 
severely reduced compared to WT recipients indicating 
an inefficient hematopoietic reconstitution in the Il2-/- 
recipients despite having higher number of HSCs (Figure 
2B). At 5 weeks, the Il2-/- recipients were consistently 
underweight (Figure 2C), and their spleens were smaller 
in size (Figure 2D) compared to WT recipients. Analysis 
of lineage-positive cells in lymphoid organs demonstrated 
a marked defect in lymphopoiesis and erythropoiesis, 
and replicated the myeloid bias of HSCs in an IL-2-
deficient environment similar to that observed in the 
Il2-/- mice (Figure 2E). Though, the thymic, splenic and 
BM cellularity improved at 11 weeks after transfer, the 
Il2-/- recipients still remained underweight (Supplementary 
Figure 2B, C). However, the increase in cellularity was not 
due to a normal hematopoiesis rather it was the outcome 
of the dysregulated hematopoiesis as shown in Figure 2E, 
with myeloid cells being the major population in these 
organs. Also, due to impaired hematopoiesis splenomegaly 
was observed at 11 weeks after cell transfer in all Il2-/- 
recipients (Supplementary Figure 2D). 
To further clarify the role of IL-2 in HSC 
maintenance and lineage differentiation, we transferred 
CD45.2+ WT or Il2-/- mice BM cells to lethally irradiated 
CD45.1+ WT hosts. Analysis at 4 weeks post-transfer 
again revealed an increased LSK cell population in the 
Il2-/- BM transferred WT recipients compared to the WT 
BM transferred mice (Figure 2F). At this time point an 
increased Sca1+ population, characteristic of the Il2-
/- mice was also observed in the Il2-/- BM transferred 
WT recipients (Supplementary Figure 2E). Analysis of 
cellularity in the lymphoid organs revealed that Il2-/- BM 
transferred WT recipients had strongly reduced thymocyte 
numbers, whereas spleen and BM cell numbers were 
comparable with that in WT BM transferred WT recipients 
(Figure 2G). However, again, the comparable cellularity in 
spleen and BM was due to impaired hematopoiesis, as all 
Il2-/- BM transferred WT recipients showed significantly 
enlarged spleen (Figure 2H), and in the BM, myelopoiesis 
was enhanced over lympho- and erythropoiesis (Figure 2I). 
This was significant as in an IL-2-sufficient environment 
even with increased number of LSK cells, Il2-/- BM cells 
failed to efficiently reconstitute the hematopoietic system.
 Interestingly, 13 weeks after BM transfer the HSC 
population in the Il2-/- BM transferred WT recipients 
were similar to that in the WT BM transferred WT 
Figure 1: Impaired maintenance of HSCs in Il2-/- mice BM. A. Flow cytometry analysis of BM cells for LSK population in WT 
and Il2-/- mice. B. Proportion of LSK cells in the BM of WT and Il2-/- mice (n = 20 per group). C. LSK cells distribution in absolute numbers 
in WT and Il2-/- mice (n = 20 per group). D. Cell size of WT and Il2-/- HSCs as reflected by their FSC distribution pattern. E. SSC distribution 
pattern of WT and Il2-/- HSCs. F. Mean cell size and granularity of WT and Il2-/- HSCs. G. FSC and SSC profiles of BM Lin-Sca1+c-Kit- 
cells from WT and Il2-/- mice. H. Profiles of WT and Il2-/- BM Lin-Sca1-c-Kit+ cells according to their FSC and SSC distribution pattern. 
I. Proportion of Lin-c-Kit+CD48-CD150+ cell population in the BM from WT and Il2-/- mice (n = 5 per group). J. Myeloid, lymphoid and 
erythroid lineage-specific genes expression in WT, Il2+/- and Il2-/- mice. K. Flow cytometry revealing the distribution of LT-HSCs and ST-
HSCs among LSK cells in indicated mice (n = 5 for WT and 4 for Il2-/- mice). L. Population distribution of LT- and ST-HSC in the BM of 
WT and Il2-/- mice based on Flk2 expression (n = 7 per group). M. Flow cytometry profiles of BM cells in WT and Il2-/- mice according to 
their FSC and SSC distribution pattern (n = 20 per group). N. Quantification of FSCloSSClo and FSChiSSChi cells in WT and Il2-/- mice. O. 
RT-PCR analysis of LT- and ST-HSC-specific genes expression in sorted LSK cells from WT and Il2-/- mice. P. Semi-quantitative RT-PCR 
on WT and Il2-/- LSK cells for critical genes involved in HSC maintenance. Q. Gene expression analysis of TFs and signaling molecules 
in LSK cells from WT, Il2+/- and Il2-/- mice. R. Cell survival and HSC proliferation-specific genes expression in LSK cells from WT, Il2+/- 
and Il2-/- mice. Numbers inside each dot plot represent percent respective population, and in histograms represent the mean fluorescence 
intensity (MFI). Data are representative of 2-5 independent experiments and shown as mean ± s.d., in (B, C & N) ***P < 0.0001, in (F) *P 
= 0.0389, ***P = 0.0001, in (I) *P = 0.0348, and in (L) ***P = 0.0002, unpaired t-test.
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recipients (Figure 2F), which in turn gave rise to efficient 
hematopoietic reconstitution resulting in comparable 
cellularity, normal body weight as well as spleen size 
(Supplementary Figure 2F-H). Also, the myeloid-biased 
hematopoiesis in IL-2-deficient background was largely 
reversed (Supplementary Figure 2I). The contrasting 
observations at an early (4 weeks) compared to a late time 
point (13 weeks) after BM cell transfer suggests that the 
reconstitution capacity of the Il2-/- HSCs is significantly 
impaired relative to the WT HSCs and require prolonged 
sensitization in an IL-2-sufficient environment in order 
to promote normal hematopoiesis. Altogether, both sets 
Figure 2: HSC maintenance in BM depends on IL-2 signaling. A. Enumeration of CD45.1+ donor-derived LSK cells distribution 
5 and 11 weeks post-transfer in the BM of irradiated CD45.2+ WT or Il2-/- recipient mice. B. Number of CD45.1+ donor-derived cells in the 
thymus, spleen and BM of irradiated CD45.2+ WT or Il2-/- recipient mice 5 weeks after transfer. C. Evaluation of body weight, and D. spleen 
weight of the recipient mice 5 weeks after cell transfer. E. Flow cytometry profiles of the distribution of various donor-derived mature 
hematopoietic cell populations in the thymus, spleen and BM of recipient mice. Data are representative of two independent experiments 
(n = 4 per group/experiment). F. Distribution of CD45.2+ WT or Il2-/- donor-derived LSK cells distribution 4 and 13 weeks post-transfer in 
the BM of irradiated CD45.1+ WT recipient mice. G. Number of CD45.2+ WT or Il2-/- donor-derived cells in the Thymus, spleen and BM 
of irradiated CD45.1+ WT recipient mice 4 weeks after transfer. H. Spleen weight of the recipient mice 4 weeks after cell transfer. I. Flow 
cytometry profiles of the distribution of various CD45.2+ WT or Il2-/- donor-derived mature hematopoietic cell populations in the thymus, 
spleen and BM of CD45.1+ WT recipient mice. Data are representative of two independent experiments (n = 4 per group/experiment). 
Numbers inside each FACS plot represent percent respective population. Data are shown as mean ± s.d., in (B) **P = 0.0090, *P = 0.0176, 
(C) **P = 0.0034, (D) **P = 0.0096, (G) **P = 0.0028, (H) *P = 0.0198, and ns = not significant, unpaired t-test.
Figure 3: Defective HSC maintenance in Il2-/- mice is T cell-mediated. A. Distribution of LSK cells in the BM of PBS or IL-2 
treated Il2-/- mice. B. Proportion of LSK cells in the BM of Il2-/- mice treated either with PBS or IL-2. C. FSC/SSC distribution of BM cells 
from PBS or IL-2 treated Il2-/- mice. D. RT-PCR analysis of Flk2 and Slamf1 expression in sorted BM LSK cells from Il2-/- mice treated 
either with PBS or IL-2. E. Flow cytometry analysis of LSK cells distribution in the BM of WT, Il2-/-, Il7ra-/- and Il2-/-Il7ra-/- mice. F. 
Quantification of the distribution of BM LSK population in indicated mice. G. Distribution of LSK cells in the BM of WT, Il2-/-, Rag1-/- and 
Il2-/-Rag1-/- mice. H. Proportion of LSK cells in BM cells from WT, Il2-/-, Rag1-/- and Il2-/-Rag1-/- mice. Numbers inside each FACS plot 
represent percent respective population. Data are representative of 3 independent experiments, (n = 4 per group) and shown as mean ± s.d., 
in (F) ***P = 0.0004 and (H) ***P < 0.0001, one-way ANOVA. 
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of experiments underline the critical requirement of IL-2 
signaling for HSC maintenance and normal hematopoiesis.
Hematopoietic defects in Il2-/- mice are T cell-
mediated
To show that IL-2 signaling directly influences HSC 
maintenance, we treated Il2-/- mice with exogenous IL-
Figure 4: Treg cell activity is critical for steady state hematopoiesis. A. LSK cells distribution in the BM of DEREG mice treated 
with PBS or diphtheria toxin (DT). B. Quantification of the LSK population distribution in DEREG mice BM after PBS or DT treatment. C. 
Cellularity in the BM and LNs of DEREG mice following PBS or DT treatment. D. Evaluation of body weight following each PBS or DT 
injection to the DEREG mice. E. Spleen weight of DEREG mice treated with PBS or DT. F. FSC/SSC distribution of BM cells from PBS 
or DT treated DEREG mice. G. Evaluation of FSCloSSClo and FSChiSSChi BM cells in PBS or DT treated DEREG mice. H. Distribution 
of LSK population in the BM of Rag1-/- mice, 3 weeks after transfer of WT CD4+CD25-CD62Lhi cells, compared to normal WT or Rag1-/- 
mice. I. Quantification of BM LSK cells in Rag1-/- mice, 3 weeks post-transfer of WT CD4+CD25-CD62Lhi cells in comparison to control 
Rag1-/- mice. J. FSC/SSC distribution of BM cells from WT CD4+CD25-CD62Lhi cells transferred Rag1-/- mice compared to control Rag1-
/- mice. K. Flow cytometry profiles of LSK cells in BM of WT, Il2-/-, Bim-/- and Il2-/-Bim-/- mice. L. Quantification of the distribution of BM 
LSK population in indicated mice. M. Photograph of spleens from WT, Il2-/-, Bim-/- and Il2-/-Bim-/- mice. Numbers inside each FACS plot 
represent percent respective population. Data are shown as mean ± s.d., in (B) **P = 0.0043, (C) *P = 0.0113 and ***P = 0.0005, (E) *P 
= 0.01734, (G) ***P = 0.0003, ***P = 0.0008, (I) ***P = 0.0006, and in (L) ***P < 0.0001 unpaired t-test. Data are representative of 3 
independent experiments, (n = 4 per group).
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2. Surprisingly, IL-2 treatment significantly reversed the 
altered pattern in HSC distribution in Il2-/- mice, which 
was now comparable to that in WT mice (Figure 3A, 3B). 
IL-2 treatment restored the missing FSCloSSClo  population 
in the BM (Figure 3C), and eventually led to resolving 
the defective hematopoiesis in Il2-/- mice (Supplementary 
Figure 3A). Also, IL-2 treatment reversed the distribution 
of HSC subpopulations, as it enhanced Flk2 and reduced 
Slamf1 expression in Il2-/- LSK cells (Figure 3D). These 
data show that IL-2 signals exert a beneficial influence 
on HSC maintenance that is essential for normal 
hematopoiesis.
Next, to investigate the basis of this strong effect 
of IL-2 signaling on HSC maintenance, we hypothesized 
that the massive T-lymphocyte proliferation reported 
in Il2-/- mice could in some way be responsible for 
the hematopoietic defects in these mice [30, 57]. To 
verify this issue, we analysed Il2-/-Il7ra-/- mice in which 
lymphoproliferation was effectively prevented [42]. 
However, analysis of LSK cells in these mice showed, 
the persistence of HSC defects both in the BM and 
in spleen as was in the Il2-/- mice (Figure 3E, 3F and 
Supplementary Figure 3B, C). To resolve this intriguing 
observation we hypothesized that most likely the residual 
T-lymphocytes do not function normally in the absence 
of IL-2 signaling and thereby induced the HSC defects 
in the Il2-/-Il7ra-/- mice. To investigate this possibility, we 
bred Il2-/- mice with Rag1-/- mice in order to abolish all 
T cells. Surprisingly, the Il2-/-Rag1-/- mice demonstrated a 
normal LSK population both in the BM (Figure 3G, 3H) 
and in the spleen (Supplementary Figure 3D, E), as well as 
a normal hematopoiesis in contrast to the Il2-/- mice. These 
observations suggest that the defective HSC maintenance 
and dysregulated hematopoiesis in the Il2-/- mice are to a 
large part mediated by T cells. 
Treg cell activity is indispensable for HSC integrity
The persistence of HSC defects in the Il2-/-Il7ra-/- but 
not in Il2-/-Rag1-/- mice raised the question of how T cell 
activity could influence hematopoiesis in the BM. IL-2 
signaling has been reported to be indispensable for Treg 
cell survival and accordingly, Il2-/- mice show a strongly 
reduced Treg cell population (Supplementary Figure 4A). 
We have shown previously that in the Il2-/-Il7ra-/- mice Treg 
cell population is also drastically reduced [42]. To prove 
that the lack of adequate number of Treg cells in the Il2
-
/-Il7ra-/- and Il2-/- mice influences HSC maintenance and 
hematopoiesis, we adopted an inducible Treg cell depletion 
model [58]. Treatment of DEREG mice with diphtheria 
toxin (DT) rapidly depleted Treg cells in these mice creating 
a situation similar to the Il2-/- mice (Supplementary Figure 
4B). Analysis of LSK cells in the DT-treated DEREG 
mice revealed a strong increase compared to the control 
PBS-treated mice (Figure 4A, 4B). Due to defective 
hematopoiesis in DT-treated DEREG mice cellularity 
in BM and peripheral lymphoid organs were enhanced 
compared to the control mice (Figure 4C). Similar to 
the Il2-/- mice, DT-treated mice, consistently lost body 
weight (Figure 4D), and showed enlarged spleen (Figure 
4E) very quickly after DT treatment indicating overall 
defects in hematopoiesis following depletion of Treg  
cells. These defects were readily evident in the BM as 
a strong reduction in FSCloSSClo cells and an increase 
in FSChiSSChi cells was observed in DT-treated animals 
compared to the control animals (Figure 4F, 4G). Ablation 
of Treg cell activity also enhanced the LSK population in 
the spleen further resembling the hematopoietic defects 
observed in the Il2-/- mice (Supplementary Figure 4C, 
D). Analysis of lineage-positive cells in the BM further 
supported the critical role of Treg cells in hematopoiesis 
as lack of Treg cell activity in the DT-treated DEREG 
mice promoted myelopoiesis (Supplementary Figure 4E-
H), an outcome similar to that in the Il2-/- mice. These 
observations suggest that in the absence of Treg cells most 
likely the activated effector T cells (Teff) activity was 
responsible for the hematopoietic defects observed in the 
IL-2 signaling-deficient mice.
To further consolidate our observation regarding 
the essentiality of Treg activity in HSC maintenance, we 
adoptively transferred Treg-depleted CD4
+ Teff cells to Rag1
-
/- mice. In contrast to control mice, Teff cells transferred 
Rag1-/- mice rapidly developed a hematopoietic phenotype 
similar to that of the Il2-/- mice. A strong increase in the 
BM LSK population (Figure 4H, 4I), concomitant with a 
decrease in FSCloSSClo BM cells (Figure 4J) reflected the 
severity of defects in HSC maintenance and hematopoiesis 
when Treg cell activity was lacking. 
Next we investigated whether restoration of Treg 
cell activity can reverse the defects in HSC maintenance 
and facilitate normal hematopoiesis in the Il2-/- mice. 
Analysis of Il2-/-Bim-/- mice in which Bim deficiency 
completely restored Treg population [42], showed normal 
hematopoiesis even if IL-2 signaling was still absent. In 
contrast to the Il2-/- mice, LSK population in BM (Figure 
4K, 4L), and spleen (Supplementary Figure 5A, B) of the 
Il2-/-Bim-/- mice was comparable to that of the control mice. 
As an immediate sign of normal hematopoiesis, the FSC/
SSC distribution of BM cells in Il2-/-Bim-/- mice showed 
normal pattern compared to the drastically reduced 
FSCloSSClo BM cells in the Il2-/- mice (Supplementary 
Figure 5C). Also, the spleen size (Figure 4M), and the 
distribution of lineage-positive cells in the Il2-/-Bim-/- mice 
were comparable with that of control mice (Supplementary 
Figure 5D). Thus, our analysis shows that the lack of Treg 
cell activity is detrimental for HSC maintenance and a Treg-
Teff homeostasis is essential for normal hematopoiesis.
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Enhanced Teff cell activity impairs HSC 
maintenance
As in steady state Treg cells keep Teff cell activity 
under control and avoid unnecessary T cell activation, 
we next investigated the phenotypes of T cells in the Il2-
/- mice. Similar to an earlier report [42], the majority of 
CD4+ T cells in the BM of Il2-/- mice were of CD62L-
CD44- activated effector phenotype in contrast to the 
prevalence of CD62L-CD44+ effector memory cells in WT 
mice (Figure 5A). These CD4+CD62L-CD44- T cells in the 
BM of Il2-/- mice were smaller in size (Figure 5B) and 
much less granular (Figure 5C) compared to the WT cells. 
To prove our assumption that activated CD4+ T 
cells can dysregulate HSC maintenance in the BM, we co-
cultured WT BM cells with unstimulated, or PMA plus 
ionomycin stimulated WT CD4+ T cells (Supplementary 
Figure 6A), in presence or absence of IL-2 on WT BM 
stromal cell layer (Figure 5D). Interestingly, co-culture 
of BM cells with activated CD4+ T cells showed an 
increase in the proportion of LSK cells, which was 
further enhanced in the presence of IL-2 (Figure 5E, 5F) 
compared to the medium controls. Even IL-2 treatment 
Figure 5: Activated T cells induce HSC defects in the BM. A. Distribution of CD4+ T cells in the BM of Il2-/- mice based on 
CD62L and CD44 expression compared to WT mice. B. Profiles of FSC distribution, and C. SSC distribution of the BM CD4+ T cells in 
WT and Il2-/- mice. D. Experimental plan to analyze the involvement of activated CD4+ T cells in BM HSC maintenance. E. Flow cytometry 
profiles showing the influence of IL-2, of naïve or activated CD4+ T cells on the maintenance of HSCs in the BM cells-stromal cells co-
culture assays. F. Quantification of LSK cells in the respective BM cells-stromal cells co-culture assays as indicated. G. Distribution of 
BM Lin-Sca1+, and H. Lin-c-Kit+ cells as evaluated from the BM cells-stromal cells co-culture assays in respective conditions as indicated. 
Numbers inside each dot plot represent percent respective population. Data are representative of 3 independent experiments, (n = 3 per 
group) and shown as mean ± s.d., in (F) **P = 0.0061, *P = 0.0185 or 0.0185 and ***P = 0.0002, (G) *P = 0.0135 or 0.0279 or 0.0143 and 
**P = 0.0029 or 0.0067, ns = not significant, one-way ANOVA.
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alone, or in combination with unstimulated CD4+ T cells 
showed a significant increase in LSK cells (Figure 5E, 5F). 
Additionally, co-culture with activated CD4+ T cells also 
showed a strong increase in the Sca1+ cells similar to the 
phenotype in Il2-/- mice, which was further increased in 
presence of IL-2 (Figure 5E, 5G). However, under each 
culture condition these anomalies in LSK and Sca1+ cells 
hardly affected the distribution of c-Kit+ cells (Figure 5E, 
5H) suggesting that the increase in LSK cells is not due 
to a mere redistribution of Lin-c-Kit+ and Lin-Sca1+ cells. 
IL-10-independent defects in HSC maintenance in 
Il2-/- mice
IL-10, produced by the Treg cells is a key player in 
the Treg-mediated immune suppression [59-61]. Deficiency 
of IL-10 has been shown to induce anemia and other 
hematopoietic anomalies [62]. Therefore, we hypothesized 
that IL-10 deficiency in the Il2-/- mice might contribute 
to the HSC defects as they have a strongly reduced Treg  
population (Supplementary Figure 4A). To check if 
IL-10 influences HSC maintenance, we analysed Cd4-
CreIl10fl/fl mice in which IL-10 production was ablated 
not only in Treg cells, but also in all T cells. Surprisingly, 
LSK cells distribution was unaffected in presence, or in 
T cell-specific loss of IL-10 activity (Figure 6A, 6B). A 
slightly decreased distribution of FSCloSSClo BM cells 
(Figure 6C), and an unaffected Lin-c-Kit+ or Sca1+ cells 
was observed in the Cd4-CreIl10fl/fl mice (Figure 6D). 
This was contrary to a recent report implicating IL-10 
in maintaining HSC homeostasis [63]. To disprove the 
notion that IL-10 produced by other hematopoietic cells 
most likely compensated for the loss of IL-10 production 
by T cells in the Cd4-CreIl10fl/fl mice, we ablated IL-
10 production in all hematopoietic cells (Vav-CreIl10fl/
fl mice). Analysis of Vav-CreIl10fl/fl mice showed a 
slight increase in BM LSK cells (Figure 6E, 6F), and an 
insignificant change in the distribution of BM FSCloSSClo 
and FSChiSSChi cells (Figure 6G). Also, the distribution 
of BM Lin-c-Kit+ or Sca1+ cells was unaffected in Vav-
CreIl10fl/fl mice compared to the WT controls (Figure 
6H). The non-involvement of IL-10 in HSC maintenance 
was also clear as we observed a strong increase in IL-10 
production in the Il2-/- T cells (Figure 6I). Thus, despite 
having increased level of IL-10, HSC maintenance was 
drastically altered in the Il2-/- mice. 
To investigate what other factors produced by the 
activated T cells in the Il2-/- mice could be involved in the 
hematopoietic abnormality, we analysed the expression 
pattern of several cytokines in these T cells. A strong 
increase in Ifng expression in addition to slightly increased 
expression of Il4, Il12b, Il23a and Tnfa was clearly 
evident in Il2-/- mice compared to WT controls (Figure 6I). 
Compared to WT mice, upon stimulation, a huge increase 
in IFN-γ producing cells was observed in the Il2-/- mice 
(Figure 6J). These observations suggest that an enhanced 
IFN-γ activity might be involved in the dysregulated 
hematopoiesis in Il2-/- mice.
Loss of IFN-γ activity rescues HSC defects in Il2-
/- mice
To explore if IFN-γ is indeed involved in the 
dysregulated hematopoiesis, and whether by abolishing 
IFN-γ activity HSC maintenance could be restored in 
the Il2-/- mice, we analysed the Il2-/-Ifng-/- mice. In stark 
contrast to the Il2-/- mice, LSK cells distribution in the Il2-
/-Ifng-/- mice was comparable with that of the littermate 
controls (Figure 7A, 7B). As a result, HSC maintenance 
was normal in the Il2-/-Ifng-/- mice and the BM regained 
its usual distribution of FSCloSSClo and FSChiSSChi cells 
(Figure 7C). IFN-γ deficiency in the Il2-/-Ifng-/- mice also 
reversed the high Sca1+ population observed in the Il2-
/- mice to WT levels without significantly affecting the 
c-Kit+ population (Figure 7D).
Abolition of IFN-γ activity not only restored the 
distribution of the LSK cells, but it also reversed the 
highly granular nature of Il2-/- HSCs to that of WT levels 
in Il2-/-Ifng-/- mice (Figure 7E). IFN-γ activity seems to be 
specifically influencing the granularity of HSCs, as the cell 
size was relatively unaffected in presence or absence of 
it (Figure 7E). In contrast, IFN-γ deficiency did neither 
influence cell size nor the granularity of Lin-Sca1+ or 
c-Kit+ cells (Supplementary Figure 6B, C). The beneficial 
effects of IFN-γ deficiency on HSCs in the Il2-/- mice were 
comparable to that observed in case of Il2-/-Bim-/- mice. 
Similar to the Il2-/-Ifng-/- mice, LSK cells in Il2-/-Bim-/- mice 
reverted back to the normal granularity when Treg activity 
was restored (Figure 7F). However, that was not the case 
in case of Il2-/-Il7ra mice, where the HSCs maintained 
higher granularity as in Il2-/- mice (Supplementary 
Figure 6D), and the defects in hematopoiesis remained 
(Figure 3E, 3F and Supplementary Figure 3B, C). As a 
result of normal HSC activity, Il2-/-Ifng-/- mice regained 
body weight (Figure 7G), and also these mice no more 
developed splenomegaly (Figure 7H, 7I). Significantly, 
IFN-γ-deficiency dramatically increased the life span of 
Il2-/- mice, which otherwise died very early in their life 
(Figure 7J). 
The hyperactive T cells in Il2-/- mice BM were 
smaller and less granular compared to the littermate 
control mice, where majority of CD4+ T cells were larger 
and more granular (Figure 7K). Abolition of IFN-γ activity 
reversed the CD4+ T cell phenotype of Il2-/- mice to that 
of WT mice (Figure 7K) suggesting this as an underlying 
mechanism, which facilitates HSC maintenance. In 
agreement with this, in Il2-/-Bim-/- mice also the BM CD4+ 
T cells regained the phenotype as in case of littermate 
control mice (Figure 7L). However, in case of Il2-/-Il7ra-/- 
mice, where HSC defects were still intact, the BM CD4+ 
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Figure 6: Dysregulated hematopoiesis in Il2-/- mice is IL-10-independent. A. Flow cytometry revealing the distribution of LSK 
cells in Cd4-CreIl10fl/fl mice compared to control mice. B. Proportion of LSK cells in the BM of Cd4-CreIl10fl/fl and Il10fl/fl mice. C. Profiles 
of BM cells in Cd4-CreIl10fl/fl mice compared to control mice according to their FSC/SSC distribution pattern. D. Evaluation of c-Kit+ and 
Sca1+ cells distribution among lineage-negative BM cells in Cd4-CreIl10fl/fl and Il10fl/fl mice. E. BM LSK cells distribution in Vav-CreIl10fl/fl 
mice compared to littermate control mice. F. Analysis of the proportion of BM LSK cells in Vav-CreIl10fl/fl and Il10fl/fl mice. G. Evaluation 
of FSCloSSClo and FSChiSSChi cells in the BM of Vav-CreIl10fl/fl mice compared to Il10fl/fl mice. H. Proportion of c-Kit+ and Sca1+ cells 
distribution among lineage-negative BM cells in Vav-CreIl10fl/fl and Il10fl/fl mice. I. Semi-quantitative RT-PCR analysis of cytokine gene 
expression in Il2-/- T cells compared to WT cells. J. Flow cytometry analysis of IFN-γ production by unstimulated or P+I stimulated CD4+ 
T cells in WT and Il2-/- mice. Numbers inside each dot plot represent percent respective population and in histograms represent the MFI. 
Data are representative of 3 independent experiments, (n = 3 per group) and shown as mean ± s.d., ns = not significant, one-way ANOVA. 
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T cells retained their smaller size and low granularity 
(Figure 7M). Thus, our study shows that abolition of 
IFN-γ activity in the absence of Treg cells (Il2-/-Ifng-/-), 
or restoring full Treg activity (Il2-/-Bim-/-) can reverse 
the abnormalities not only in HSCs but also in the CD4+ 
T cells in the BM, which were the prime cause of the 
hematopoietic abnormalities in Il2-/- mice.
DISCUSSION
We have previously reported a severely defective 
erythropoiesis in Il2-/- mice due to the lack of KLF1 
activity in erythroid precursor cells [42]. Also, earlier 
studies have reported severe autoimmunity, colitis and 
other pathological conditions in Il2-/- mice [57, 64, 65]. 
However, defects at the level of HSC resulting in a highly 
dysregulated hematopoiesis threatening the survival 
of these animals have so far not been investigated. 
Maintenance of HSC quiescence and subsequent multiple 
lineage differentiation are governed by an array of 
signalling pathways and TFs. A role for IL-2 in HSC 
maintenance has not been elucidated though altered HSC 
distribution in these mice has been reported [66]. Here 
using multiple gene-manipulated mice we show that 
IL-2 signaling is an essential component of the complex 
regulatory mechanisms that need to be in place to maintain 
HSC integrity and steady state hematopoiesis. 
Our findings of dysregulated Notch-Runx and 
other signalling molecules in HSCs lacking IL-2 signals 
is a critical attribute in explaining how the HSCs in Il2-
/- mice lose their quiescence and give rise to a myeloid-
biased hematopoiesis. The HSCs in Il2-/- mice are 
phenotypically distinct from that of WT mice, as they are 
highly granular (Figure 1D). This was a specific effect of 
IL-2 deficiency on HSCs only, as the Sca1+ or c-Kit+ cells 
were similar to that of WT cells, even though the Sca1+ 
population was strongly increased in Il2-/- mice (Figure 
1A). The observations regarding altered Flk2 and Slamf1 
expression in Il2-/- HSCs (Figure 1O), further vindicate an 
abnormal HSC maintenance in Il2-/- mice. Besides, from 
our gene expression analysis of TFs and various signalling 
molecules involved in maintaining HSC quiescence 
(Figure 1P, 1Q), it is clear that the defects in Il2-/- HSCs 
are specific defects arising out of IL-2 deficiency. The loss 
of FSCloSSClo cells and the accumulation of FSChiSSChi 
cells in the BM was a characteristic phenotype and could 
be used as a diagnostic trait for defective hematopoiesis 
in absence of IL-2 signals (Figure 1M, 1N). The fact that 
all these defects could be reversed with the treatment of 
IL-2 to the Il2-/- mice (Figure 3A-3D and Supplementary 
Figure 3A) suggests that IL-2 signaling has an important 
contribution in maintaining HSCs in the BM. The 
hematopoietic phenotype observed in both our settings 
(Figure 2 and Supplementary Figure 2) at an early and late 
time points after adoptive transfer of BM cells, indicate 
that IL-2 signaling is critical in maintaining normal BM 
hematopoiesis. 
Contrary to Il2-/-Rag1-/- mice (Figure 3G, 3H and 
Supplementary Figure 3D, E) the persistence of the 
HSC defects in Il2-/-Il7ra-/- mice (Figure 3E, 3F and 
Supplementary Figure 3B, C) underlines the important 
role T cells play in the maintenance of HSCs. The 
phenotype of T cells in the BM of Il2-/- mice is very 
distinct compared to that in WT mice (Figure 5A), and we 
have previously reported that these activated T cells in the 
Il2-/- mice cause severe defects in erythrocyte development 
[42]. Here also, we have unravelled a link between intact 
Treg activity establishing control over Teff cell activities, 
which is absolutely necessary for maintaining HSC 
integrity and normal hematopoiesis. Lack of optimal Treg 
population in the Il2-/- mice initiates the cascading effect 
of activated Teff cells producing excess amount of IFN-γ, 
which in turn destabilizes the HSC physiology leading 
to defective hematopoiesis. Involvement of the Treg cells 
in maintaining HSC integrity and in hematopoiesis was 
clearly evident in our inducible Treg depletion model 
(Figure 4A-G). Further, our analysis of the Il2-/-Bim-/- mice, 
where restoration of Treg activity prevented the loss of HSC 
quiescence and maintained hematopoiesis (Figure 4K, 4L 
and Supplementary Figure 5), suggests that the Treg cells 
could actually fix the hematopoietic defects in Il2-/- mice. 
How do the Treg cells exert such a profound influence 
on HSC integrity? Treg cells are a prime source of IL-10, 
and a recent study has implicated IL-10 signaling to be 
critical for maintaining HSC quiescence [60, 61, 63]. 
However, in addition to the normal HSC phenotype 
and hematopoiesis observed in the Cd4-CreIl10fl/fl and 
Figure 7: Enhanced IFN-γ activity leads to dysregulated hematopoiesis in Il2-/- mice. A. Distribution of LSK cells in BM 
from WT, Il2-/-, Ifng-/- and Il2-/-Ifng-/- mice. B. Quantification of BM LSK cells in Il2-/-Ifng-/- mice compared to WT, Il2-/-and Ifng-/- mice. C. 
Distribution of BM cells in indicated mice according to their FSC and SSC pattern. D. Evaluation of c-Kit+ and Sca1+ cells distribution 
among lineage-negative BM cells in Il2-/-Ifng-/- mice compared to littermate control mice. E. FSC and SSC patterns of Il2-/-Ifng-/- LSK cells 
compared to that of WT, Il2-/- and Ifng-/- cells. F. FSC and SSC patterns of Il2-/-Bim-/- LSK cells compared to that of WT, Il2-/- and Bim-/- 
cells. G. Body weight, H. spleen weight, and I. splenocytes number in Il2-/-Ifng-/- mice compared to WT, Il2-/-and Ifng-/- mice. J. Survival 
curve for Il2-/-Ifng-/- mice compared to WT, Il2-/-and Ifng-/- mice. K. Profile of Il2-/-Ifng-/- BM CD4+ T cells according to their FSC and SSC 
distribution pattern compared to that of littermate control mice. L. FSC and SSC distribution of Il2-/-Bim-/- BM CD4+ T cells compared to 
that of littermate control mice. M. Profile of Il2-/-Il7ra-/- BM CD4+ T cells according to their FSC and SSC distribution pattern compared 
to that of WT, Il2-/-and Il7ra-/- mice. Numbers inside each dot plot represent percent respective population and in histograms represent the 
MFI. Data are representative of 3 independent experiments, (n = 3 per group) and shown as mean ± s.d., in B, D, G, H & I ***P < 0.0001, 
ns = not significant, one-way ANOVA.
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Vav-CreIl10fl/fl mice (Figure 6A-6H), our finding of an 
increased IL-10 production in the Il2-/- mice (Figure 6I) 
suggests that the HSC defects in these mice are IL-10-
independent. On the other hand, the reversal in HSC 
defects in Il2-/-Ifng-/- mice (Figure 7) demonstrated that 
increased IFN-γ activity was the main reason behind 
the dysregulated hematopoiesis in Il2-/- mice. Our study 
unravelled the contrasting activities of IL-2 and IFN-γ, 
produced by the lymphocytes on HSC physiology and on 
hematopoiesis. IL-2 being the guarantor of Treg survival 
and activity keeps the T cell activation in the BM under 
check resulting in minimal IFN-γ in the HSC niche. This 
in turn ensures optimal Notch-Runx signalling maintaining 
the HSC quiescence and normal hematopoiesis 
(Supplementary Figure 7). Any defects in IL-2 signaling 
will rapidly lead to Treg cell death and breaking the delicate 
balance between Treg and Teff cell activity resulting in an 
excess IFN-γ having detrimental effect on hematopoiesis 
(Supplementary Figure 7). IFN-γ signalling has been 
reported to play a role in HSC maintenance and our study 
further supports this activity [67-69]. 
Our finding that an optimal number of Treg cells are 
critical for HSC integrity will have wide impact in the 
clinical contexts of HSC reconstitution. Hematopoietic 
dysfunction is common following radio- or chemotherapy 
of patients suffering from various forms of cancer. 
Further, the observation regarding abolition of IFN-γ 
activity restoring hematopoiesis even in the absence of 
Treg cells will foster the use of anti-IFN-γ in facilitating 
hematopoietic reconstitution in varied settings. In addition, 
while deciding on clinical remedies in the context of 
hematopoietic reconstitution the contrasting activities 
of both IL-2 and IFN-γ need to be carefully evaluated 
keeping in mind their important role in T cell function.
MATERIALS AND METHODS
Mice
C57BL/6 wild-type, Il2-/-, Il2ra-/-, Il7ra-/-, Jak3-/-, 
Rag1-/-, Bim-/-, DEREG, Il2-/-Il7ra-/-, Il2-/-Rag1-/-, Il2-/-Bim-/-, 
Il10fl/fl, Cd4-CreIl10fl/fl, Vav-CreIl10fl/fl, Ifng-/- and Il2-/-Ifng-/- 
mice of 6-8 weeks age unless mentioned otherwise were 
used in this study. All mice used in the study were on 
C57BL/6 background. Animals were housed either in the 
central animal facility (ZEMM) or in the animal facility of 
the Institute of Virology and Immunobiology, University 
of Würzburg, according to standard animal care protocols. 
All animal experiments were performed with extreme care, 
and were according to established guidelines (approved 
by the Regierung von Unterfranken, Wuerzburg, Permit 
Number 55.2-2531.01-53/10B). 
Flow cytometry
All antibodies for flow cytometry and cell 
isolation were purchased either from BD Pharmingen or 
eBioscience. Anti-Ly-6A/E (Sca1; D7), anti-c-Kit (2B8), 
Biotin mouse lineage panel (# 559971), anti-CD45R/B220 
(RA3-6B2), anti-CD3ε (145-2C11), anti-CD4 (GK1.5), 
anti-CD8α (53-6.7), anti-CD11b (M1/70), anti-CD11c 
(N418), anti-CD25 (PC61), anti-CD41 (MWReg30), 
anti-CD44 (IM7), anti-CD45.1 (A20), anti-CD45.2 (104), 
anti-CD48 (HM48-1), anti-CD62L (MEL-14), anti-Ly-6G 
(Gr1; RB6-8C5), anti-F4/80 (BM8), anti-NK1.1 (PK136), 
anti-Ter119 (TER-119), anti-CD127 (A7R34), anti-
CD135 (Flk2; A2F10), anti-CD150 (9D1), anti-Foxp3 
(FJK-16s), anti-IFN-γ (XMG1.2), anti-IgM (R6-60.2) and 
anti-IgD (11-26c), antibodies either directly conjugated 
with fluorochromes or with biotin were used throughout 
this study. Biotinylated antibodies were revealed with 
secondary streptavidin-allophycocyanin or phycoerythrin-
Cy5 (PE-Cy5) antibodies. HSC (LSK) population in BM 
was analyzed by gating either on lineage-negative cells 
not expressing IL-7Rα and high levels of both Sca1 and 
c-Kit molecules, or on LSK cells negative for CD48 and 
positive for high levels of CD150 expression. LT- and 
ST-HSCs were analyzed by further gating on LSK cells 
for Flk2 (CD135) expression. Flow cytometry and data 
analysis were performed following standard procedure 
using FACSCalibur and CellQuest or FlowJo software. 
Cell sorting
For cell sorting, femur and tibia from both hind 
limbs were collected and the bone marrow was flushed out 
by pumping BSS containing 0.1% BSA with the help of 
a syringe and needle. Single cell suspension was prepared 
and cells were washed once in BSS/BSA and then 
with PBS/0.1% BSA. Afterwards, total BM cells were 
incubated with biotinylated antibodies against lineage 
markers (anti-CD3, anti-B220, anti-CD11b/CD11c, anti-
Gr1, and anti-Ter119) followed by incubation with anti-
biotin microbeads. Lineage-positive and lineage-negative 
cells were isolated by magnetic separation. Lineage-
negative fraction was further incubated with anti-IL-7Rα 
(CD127), anti-Sca1, anti-c-Kit and anti-Flk2 antibodies 
for sorting of LSK cells, or the LT- and ST-HSCs. Cells 
were sorted by using a FACSAria (BD Biosciences) flow 
cytometer. 
Intracellular staining
For intracellular IFN-γ staining, 5 x 106 total BM 
cells from WT and Il2-/- mice were either cultured in 
complete-RPMI (10% FCS) medium or stimulated with 
PMA plus Ionomycin (100 ng each) for 5 h in presence 
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of GolgiPlug (1:1000 dilution) and Monensin (1:1500 
dilution). For intracellular Foxp3 staining, freshly isolated 
5 x 106 splenocytes from WT and Il2-/- mice, or BM, spleen 
and LN cells from PBS or DT treated DEREG mice were 
used. Cells were first surface stained for CD4, CD8 and 
CD25 followed by intracellular IFN-γ or Foxp3 staining 
according to eBioscience Foxp3 staining protocol. IFN-γ 
expression in the BM was analyzed by gating on CD4+ 
T cells. Similarly, Foxp3 expression in each case was 
analyzed by gating on CD4+CD25+ T cells (WT and Il2-
/- mice) or by evaluating GFP levels in DEREG mice. 
Flow cytometry was performed using a FACSCalibur 
(BD Biosciences) and data were analyzed using FlowJo 
software.
Photographs
Photograph of spleens were taken using a Nikon 
Coolpix 4500 digital camera, and the photographs were 
processed using Adobe Photoshop software.
Adoptive cell transfer
Single cell suspensions of BM cells were prepared 
and RBCs were lysed before transfer. For adoptive 
transfer, in the first set of experiments 4 x 106 BM cells 
from CD45.2+ WT or Il2-/- donors were transferred 
to lethally (9 Gy) irradiated CD45.1+ congenic WT 
recipients. In the reverse set of experiments BM cells from 
CD45.1+ WT donors were transferred to lethally irradiated 
CD45.2+ WT or Il2-/- recipients by retro-orbital injection 
of the venous sinus. Post-cell transfer, recipient mice were 
maintained with antibiotic-supplemented drinking water 
and were treated with extra care. BM hematopoiesis was 
analyzed at 5 and 11 weeks (CD45.2+ WT or Il2-/- donor 
cells), or at 4 and 13 weeks (CD45.1+ WT donor cells) 
after transfer by gating on donor-derived cells in each set 
of experiments. For the transfer of naïve CD4+ Teff cells, 
2.0 x 106 CD4+CD25-CD62Lhi cells from LN and spleen 
were transferred intraperitoneally to Rag1-/- mice, and, 
three weeks post-transfer, frequency of LSK cells in the 
BM was analyzed.
In vivo injections
6-8 weeks old Il2-/- mice were injected every 
alternate day with 1 µg recombinant murine IL-2 (rmIL-2, 
Peprotech) or an equal volume of PBS intraperitoneally 
for two weeks. Mice were analyzed to investigate the 
effects of rmIL-2 on BM hematopoiesis four days after 
the last injection. DEREG mice of 6 weeks of age were 
either injected with 1 µg (100 µl) diphtheria toxin (DT) 
or an equal volume of PBS intraperitoneally for four 
consecutive days. Subsequently, three days after last 
injection mice were analyzed for the effect of lack of Treg 
cell activity on BM hematopoiesis. 
In vitro co-culture assay
Establishment of BM stromal cell layer: 20 x 106 
total BM cells from WT mice were plated into each well 
of a 24-well plate in 2 ml complete-RPMI (10% FCS) 
medium. Cells were incubated at 37° C and after 3 days all 
floating cells were removed and the adherent stromal cells 
were washed with complete-RPMI (10% FCS) medium. 
Cells were washed every 4 days and fresh medium was 
added to allow the stromal cells to grow up to confluency. 
At day 28, 5 x 106 freshly isolated WT BM cells were 
added to the stromal cell layer and were co-cultured with 4 
x 105 unstimulated or 6 h PMA plus ionomycin stimulated 
WT CD4+ T cells in presence or absence of IL-2 (2 ng/
ml). After 60 h, the cultures were analyzed to evaluate 
the influence of T cell activity on LSK cells in respective 
culture condition. 
Semiquantitative RT-PCR
Sorted LSK cells were used to synthesize cDNA 
using Miltenyi Biotec cDNA synthesis kit and protocol. 
Semiquantitative RT-PCR was performed to analyze 
the expression of indicated genes. Primer sequences are 
available in the supplementary information online.
Statistics
Results are presented as mean ± s.d. Statistical 
significance was assessed using Student’s t-test for 
comparison between two groups and ANOVA for the 
differences between groups.
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